Loading
Every dated change on the records linked to Early triple-negative breast cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Primary DFS endpoint not met (figures not indexed); exploratory: avelumab benefit only with baseline TILs 30% or more (stratum B 3-year DDFS 92.
pCR 58% (48 to 67); RCB 0 or 1 69%; 3-year EFS 86% (98% with pCR, 68% without).
Germline BRCA group: three-year survival 100 percent (39 patients, one relapse) with the gap schedule versus 88 percent (45 patients, nine relapses) with chemotherapy alone (University of Cambridge release on the Nature 2024 paper).
A milestone in how this cancer is treated.
Closed for futility: platinum not superior or non-inferior to capecitabine for iDFS in basal-like residual TNBC (primary hazard ratio not indexed).
iDFS HR 0.
5-year DFS 82.
A milestone in how this cancer is treated.
DFS HR 0.
Pathological complete response 58% vs 41% (all patients); 69% vs 49% in PD-L1-positive disease.
EFS HR 0.
A milestone in how this cancer is treated.
Carboplatin increased pathological complete response and improved disease-free survival in triple-negative breast cancer, without benefit in HER2-positive disease.
A milestone in how this cancer is treated.